A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
NCT00571389
Recruiting
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral blood of cancer patients and healthy volunteers by using specific conjugated antibodies, evaluating their functional ex vivo anti-tumor cytotoxicity against targeted autologous tumor cells.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
05/12/2025
Locations: Carolina BioOncology Institute, Huntersville, North Carolina
Conditions: Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
Register for Updates
A Study of SGN-B6A in Advanced Solid Tumors
NCT04389632
Recruiting
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedoti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Alaska Oncology and Hematology, Anchorage, Alaska +153 locations
Conditions: Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Carcinoma, Non-small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms, HER2 Negative Breast Neoplasms, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Register for Updates
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318
Recruiting
This is an open-label, phase 1/2, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Mayo Clinic, Rochester, Minnesota +3 locations
Conditions: Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Register for Updates
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.
NCT05704361
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with multiple sclerosis (MS).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/12/2025
Locations: Stanford University Medical Center, Stanford, California +31 locations
Conditions: Multiple Sclerosis
Register for Updates
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
NCT06058988
Recruiting
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent Glioblastoma
Register for Updates
Enhancing Digitally Delivered Diabetes Education With Real-Time CGM
NCT06296550
Recruiting
The current research study will add continuous glucose monitoring devices to the evidence-based text messaging diabetes education program for patients with type 2 diabetes for 6 months. Results on the effectiveness of this intervention will be compared for non-insulin using patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Scripps Whittier Diabetes Institute, San Diego, California
Conditions: Diabetes Type 2
Register for Updates
Supporting Evidence-based Responses to Emotional Needs in Emphysema
NCT06600126
Recruiting
The goal of this clinical trial is to understand how a Coping Skills Training program can reduce depression and anxiety in people with chronic obstructive pulmonary disease (COPD), particularly those who face health disparities, including those with low income, different racial backgrounds, or those living in rural areas. The main questions it aims to answer are: * How does the Coping Skills Training program help reduce stress and anxiety in patients? * What causes variations in the effectivene... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Henry Ford Health System, Detroit, Michigan +1 locations
Conditions: COPD
Register for Updates
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373
Recruiting
This study is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 patients will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Mayo Clinic - Scottsdale, Scottsdale, Arizona +39 locations
Conditions: VEXAS, VEXAS Syndrome
Register for Updates
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT02422641
Recruiting
Management of leptomeningeal disease (LMD) in patients with metastatic breast cancer is an area of unmet clinical need. High-dose methotrexate (HD-MTX) is known to have activity against breast cancer and in contrast to other systemic chemotherapeutics, it penetrates the blood brain barrier, targets areas of poor cerebrospinal fluid flow, may penetrate bulky leptomeningeal disease, and provide treatment to systemic disease burden. While two retrospective studies have suggested activity of HD-MTX... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +2 locations
Conditions: Metastatic Breast Cancer, Leptomeningeal Disease
Register for Updates
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226
Recruiting
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Urology Centers of Alabama, PC, Homewood, Alabama +375 locations
Conditions: Cancer
Register for Updates
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416
Recruiting
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be app... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Banner Gateway Medical Center, Gilbert, Arizona +223 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
NCT05721937
Recruiting
The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring. The study is seeking participants who: * Are currently or recently pregnant * Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR have a diagnosis of moderate-to-severe atopic dermatitis All participants in this study will receive treatment according to routine care, as this is an observational study. The exposed group will c... Read More
Gender:
FEMALE
Ages:
0 years and above
Trial Updated:
05/12/2025
Locations: Pfizer, New York, New York
Conditions: Atopic Dermatitis
Register for Updates